ArticleHematology, transfusion and cell therapy
Real-world data of autologous stem cell transplantation for patients with mantle cell lymphoma in Argentina.
Article in Hematology, transfusion and cell therapy. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundFor eligible patients with mantle cell lymphoma who respond to induction therapy, first-line consolidation with autologous hematopoietic progenitor cell transplantation remains a standard treatment. However, outcomes for these patients in Argentina have not been fully characterized. This paper aims to describe the factors linked to improved survival of patients with mantle cell lymphoma after transplantation in Argentina. In addition, the association between relapse within the first 24 months after transplant and overall survival was evaluated.
methodsA retrospective, multicenter study was carried out. Patients over 18 years of age with a diagnosis of mantle cell lymphoma who received autologous hematopoietic progenitor cell transplantation from 2007-2023 at centers affiliated with the Argentine Group for Bone Marrow Transplantation and Cellular Therapy (GATMO-TC) were included. For the survival analysis, a landmark approach was utilized: overall survival was calculated from the date of progression for the group that relapsed within 24 months, and from the 24-month post-transplantation landmark for those who did not.
resultsOne hundred and sixty-six patients from nine Argentine centers were included, 128 of whom were men (77%). The median age at transplantation was 58 years. Eighteen (11%) had blastoid morphology. The pretransplant status was complete response in 145 (87%) patients. With a median follow-up of 38.4 months, the median overall survival and progression-free survival were 102 and 48.8 months, respectively. In the multivariate analysis, the blastoid variant, an age ≥55 years, and a transplant comorbidity index ≥2 were independent predictors of survival.
conclusions>70% achieved prolonged survival. Blastoid morphology, age older than 55 years, and comorbidities diminished outcomes after transplantation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.